Krystal Biotech (KRYS) Other Non-Current Liabilities (2018 - 2026)

Krystal Biotech's Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 162.37% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $5.1 million (up 162.37% YoY), while the FY2025 annual figure was $3.7 million, up 160.75% from the prior year.
• Other Non-Current Liabilities came in at $5.1 million for Q1 2026 at Krystal Biotech, up from $3.7 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $5.1 million in Q1 2026 to a low of $588000.0 in Q2 2024.
• A 3-year average of $2.4 million and a median of $2.4 million in 2025 frame the typical range for Other Non-Current Liabilities.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 376.19% in 2025 and fell as far as 160.75% in 2025.
• Krystal Biotech's Other Non-Current Liabilities stood at $1.4 million in 2024, then surged by 160.75% to $3.7 million in 2025, then soared by 38.49% to $5.1 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $5.1 million, $3.7 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison